Find

What it reported doing in 2024

Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluat

Financial Efficiency

• Mission deployment rate: 93.9%; rating input score 94
• Program expense ratio: 81.2%; rating input score 81
• Fundraising efficiency: $66.93 raised per $1 spent on fundraising; rating input score 80; 80th percentile among comparable filings

Transparency & Controls

• Consistency checks: 93.3%; rating input score 93; 14th percentile among comparable filings
• Pay-setting controls: 2 of 6 controls in place; rating input score 33
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: 2 of 8 controls in place; rating input score 25
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Fail
  • Conducts field audits: Fail
  • May suspend future funding: Fail
  • Requires financial reports: Fail
  • Conducts site visits: Pass
  • Requires grant agreements: Fail
  • May require repayment: Fail
• Grant itemization coverage: 100%; rating input score 100; 72nd percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Yes; rating input score 100

Accountability

• Independent voting board: 100%; rating input score 100; 66th percentile among comparable filings
• Governance controls: 8 of 9 controls in place; rating input score 89
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Fail
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: -15.3%; rating input score 7; 7th percentile among comparable filings
• Total-asset coverage ratio: 0.9; rating input score 32; 32nd percentile among comparable filings
• Liabilities to assets ratio: 0.83; rating input score 13; 13th percentile among comparable filings
• Officer compensation ratio: 7.8%; rating input score 31; 31st percentile among comparable filings

Growth

• Program expense growth: -10.8% per year; rating input score 0; 2nd percentile among comparable filings
• Revenue growth: -12.3% per year; rating input score 0; 1st percentile among comparable filings
• Asset growth: -15.1% per year; rating input score 0; 1st percentile among comparable filings